| UNH |
Report |
Operating EPS (Q2 2026) |
BEAT |
pred ~$5.10 vs. cons $4.84 |
MEDIUM |
| UNH |
Report |
Medical Care Ratio (Q2 2026) |
IN-LINE |
pred ~87.8% vs. cons 88.45% |
MEDIUM |
| UNH |
Report |
OptumHealth Operating Income (Q2 2026) |
BEAT |
pred ~$650M vs. cons $532M |
MEDIUM |
| UNH |
Guide |
Adj. EPS (FY2026) |
BETTER |
guide >$18.75 vs. cons $18.51 |
MEDIUM |
| UNH |
Guide |
MCR (FY2026) |
UNCHANGED |
guide 88.8% +/-50bps maintained vs. cons 88.49% |
HIGH |
| UNH |
Guide |
Buyback / Capital (qualitative) |
BETTER |
Confirm >=2B H1 complete; H2 continuation signaled |
HIGH |
| UNH |
Return |
Day-1 residual (stock − beta × S&P 500) |
+4.0% |
— |
MEDIUM |
| UNH |
Return |
5-day cumulative residual |
+6.0% (FOLLOW-THROUGH) |
FOLLOW-THROUGH — H2 estimate revisions chase the implied FY lift; sell-side models lift Q3/Q4 on the guide raise |
MEDIUM |